SCHEMBL21274809

SCHEMBL21274809

O=C(O)n1ccc(OCC2(C(F)(F)F)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CFTR P13569 19/20 0.40
SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20029658 0.88 CFTR (0.40) CFTR
SCHEMBL20582065 0.87 CFTR (0.42) CFTR
SCHEMBL21245162 0.86 CFTR (0.38) CFTR
SCHEMBL21245268 0.85 PKM (0.32) CFTR
SCHEMBL20023965 0.85 CFTR (0.39) CFTR
SCHEMBL21244608 0.84 CFTR (0.34) CFTR
SCHEMBL21244445 0.83 CFTR (0.33) CFTR
SCHEMBL21245052 0.83 CFTR (0.37) CFTR
SCHEMBL20029455 0.80 CFTR (0.40) CFTRSCN9A
SCHEMBL20029653 0.78 CFTR (0.37) CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752510-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM Vertex Pharmaceuticals Incorporated (US) 2020-12-23 EP disclosed
WO-2019161078-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-22 WO disclosed